Leder BZ, Zapalowski C, Hu MY, et al. - In this prespecified analysis, researchers ascertained if the fracture risk decreases and the BMD gains observed with abaloparatide/alendronate in ACTIVExtend were consistent across prespecified subgroups categorized by baseline risk. In ACTIVE, participants in the study were randomized 1:1:1 to placebo or abaloparatide 80 μg daily in a blinded fashion or to open-label teriparatide 20 μg daily for 18 months. No clinically meaningful interaction was observed between treatment assignment and any baseline risk variable. In the abaloparatide/alendronate group, BMD gains were higher in the lumbar spine, total hip, and femoral neck compared with placebo/alendronate group. For a wide range of postmenopausal women at risk for osteoporotic fractures, the sequence of abaloparatide for 18 months followed by alendronate for up to 24 months seems to be an effective treatment option.